Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
Public ClinicalTrials.gov record NCT05665387. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
OPSIS: A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase IIa study to assess efficacy and safety of STN1013600 ophthalmic solution (0.1%, and 0.3 %), twice daily when compared to Placebo in subjects diagnosed with presbyopia. This study will consist of a Screening Period of up to 15 days followed by a 2 Month Treatment Period. After the Treatment Period subjects will be followed for a one-month treatment free period.
Study identification
- NCT ID
- NCT05665387
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 79 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 47 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 22, 2022 (Actual)
- Primary completion
- Jul 27, 2023 (Actual)
- Completion
- Jul 27, 2023 (Actual)
- Last update posted
- May 29, 2024
2022 – 2023
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Global Research Management Inc | Glendale | California | 91204 | — |
| Eye Research Foundation | Newport Beach | California | 92663 | — |
| Clayton Eye Clinical Research, LLC | Morrow | Georgia | 30260 | — |
| Comprehensive Eye Care, Ltd | Washington | Missouri | 63090 | — |
| Rochester Ophthalmological Group, P.C. | Rochester | New York | 14618 | — |
| Asheville Eye Associates | Asheville | North Carolina | 28803 | — |
| Scott Christie and Associates PC | Cranberry Township | Pennsylvania | 16066 | — |
| Vance Thompson Vision Clinic | Sioux Falls | South Dakota | 57108 | — |
| University Eye Specialists | Maryville | Tennessee | 37803 | — |
| Total Eye Care PA | Memphis | Tennessee | 38119 | — |
| The Cataract and Glaucoma Center | El Paso | Texas | 79902 | — |
| R and R Eye Research LLC | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05665387, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 29, 2024 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05665387 live on ClinicalTrials.gov.